SI3067417T1 - Izboljšani postopki čiščenja vektorjev rekombinantnega AAV - Google Patents

Izboljšani postopki čiščenja vektorjev rekombinantnega AAV

Info

Publication number
SI3067417T1
SI3067417T1 SI201031783T SI201031783T SI3067417T1 SI 3067417 T1 SI3067417 T1 SI 3067417T1 SI 201031783 T SI201031783 T SI 201031783T SI 201031783 T SI201031783 T SI 201031783T SI 3067417 T1 SI3067417 T1 SI 3067417T1
Authority
SI
Slovenia
Prior art keywords
purification
improved methods
aav vectors
recombinant aav
recombinant
Prior art date
Application number
SI201031783T
Other languages
English (en)
Inventor
Paulene Mclean Quigley Sheldon
Peter S. Gagnon
Gina Nichols
Barbara A. Thorne
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of SI3067417T1 publication Critical patent/SI3067417T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicinal Preparation (AREA)
SI201031783T 2009-06-16 2010-06-16 Izboljšani postopki čiščenja vektorjev rekombinantnega AAV SI3067417T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18760109P 2009-06-16 2009-06-16
EP16166278.8A EP3067417B1 (en) 2009-06-16 2010-06-16 Improved methods for purification of recombinant aav vectors

Publications (1)

Publication Number Publication Date
SI3067417T1 true SI3067417T1 (sl) 2018-11-30

Family

ID=43356746

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201031783T SI3067417T1 (sl) 2009-06-16 2010-06-16 Izboljšani postopki čiščenja vektorjev rekombinantnega AAV
SI201032079T SI3444335T1 (sl) 2009-06-16 2010-06-16 Izboljšani postopki čiščenja vektorjev rekombinantnega AAV

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201032079T SI3444335T1 (sl) 2009-06-16 2010-06-16 Izboljšani postopki čiščenja vektorjev rekombinantnega AAV

Country Status (24)

Country Link
US (3) US10017746B2 (sl)
EP (4) EP3067417B1 (sl)
JP (3) JP5956331B2 (sl)
KR (2) KR20180000341A (sl)
CN (2) CN102803478B (sl)
BR (1) BRPI1015176B1 (sl)
CA (2) CA3077531C (sl)
CY (3) CY1117936T1 (sl)
DK (2) DK3444335T3 (sl)
ES (3) ES2881050T3 (sl)
HK (1) HK1165830A1 (sl)
HR (2) HRP20181743T1 (sl)
HU (3) HUE054940T2 (sl)
IL (3) IL216960A (sl)
LT (2) LT3444335T (sl)
MX (2) MX2011013613A (sl)
PL (2) PL2443233T3 (sl)
PT (3) PT2443233T (sl)
RS (2) RS62086B1 (sl)
RU (1) RU2016119739A (sl)
SG (2) SG10201403290SA (sl)
SI (2) SI3067417T1 (sl)
TR (1) TR201815937T4 (sl)
WO (1) WO2010148143A1 (sl)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400235T3 (es) 2006-04-28 2013-04-08 The Trustees Of The University Of Pennsylvania Método de producción escalable de AAV
CA3077531C (en) 2009-06-16 2022-09-20 Genzyme Corporation Improved methods for purification of recombinant aav vectors
CA2787009C (en) 2010-01-15 2018-04-03 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
US8895707B2 (en) 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
US9592540B2 (en) 2011-02-02 2017-03-14 Bio-Rad Laboratories, Inc. Apatite surface neutralization with alkali solutions
EP3318571B1 (en) 2011-03-16 2021-02-17 F. Hoffmann-La Roche AG Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
EP2700399B1 (en) * 2011-04-18 2017-05-31 National Center of Neurology and Psychiatry Drug delivery particles and method for producing same
ES2558168T3 (es) 2011-09-08 2016-02-02 Uniqure Ip B.V. Eliminación de virus contaminantes en preparaciones AVV
US9815695B2 (en) 2012-05-30 2017-11-14 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
EP2854980B1 (en) * 2012-05-31 2017-11-01 Agency For Science, Technology And Research Selective binding of biological targets to solid phase ureides
GB2525562B (en) * 2013-02-15 2017-10-11 T Gjerde Douglas Methods for purification of biological cells
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
KR102200278B1 (ko) * 2013-03-15 2021-01-07 더 칠드런스 호스피탈 오브 필라델피아 무혈청 현탁 세포 배양 시스템에서 재조합 렌티바이러스 벡터를 생성하기 위한 확대가능한 제작 방법
EP2986310B1 (en) 2013-04-17 2020-08-05 Genzyme Corporation Compositions for treating and preventing macular degeneration
KR102069561B1 (ko) * 2013-07-11 2020-01-23 다카라 바이오 가부시키가이샤 외피 비보유 바이러스의 제조 방법
TWI687225B (zh) 2014-02-06 2020-03-11 美商健臻公司 用於治療及預防黃斑部病變的組成物及方法
IL292951B1 (en) 2014-05-02 2024-06-01 Genzyme Corp AAV vectors for gene therapy in the central nervous system and retina
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3157551B1 (en) 2014-06-23 2023-02-15 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
CN105392569B (zh) 2014-06-23 2019-08-20 生物辐射实验室股份有限公司 磷灰石预处理
WO2016006658A1 (ja) 2014-07-10 2016-01-14 タカラバイオ株式会社 非エンベロープウイルス粒子の製造方法
CN104232687A (zh) * 2014-09-17 2014-12-24 许瑞安 一种重组腺相关病毒rAAV载体的分离纯化方法
CA2966620A1 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
EP3243904A4 (en) 2015-01-09 2018-06-27 Takara Bio Inc. Method for producing non-enveloped viral particles
US10429288B2 (en) 2015-01-20 2019-10-01 Genzyme Corporation Analytical ultracentrifugation for characterization of recombinant viral particles
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3054006A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
PL3256594T3 (pl) 2015-02-10 2022-02-14 Genzyme Corporation Ulepszone dostarczanie cząstek wirusa do prążkowia i kory
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
CN105907729B (zh) * 2015-05-05 2019-08-16 广东东阳光药业有限公司 一种制备人***瘤病毒l1蛋白类病毒样颗粒的方法
US20170067028A1 (en) * 2015-05-15 2017-03-09 Douglas J. Ballon Radiolabeling of adeno associated virus
JP6985250B2 (ja) 2015-05-16 2021-12-22 ジェンザイム・コーポレーション 深部イントロン突然変異の遺伝子編集
US9663766B2 (en) 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
US11098286B2 (en) 2015-12-11 2021-08-24 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV9
WO2017100674A1 (en) * 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
US11028372B2 (en) 2015-12-11 2021-06-08 The Trustees Of The University Of Pennsylvania Scalable purification method for AAVRH10
ES2934848T3 (es) 2015-12-11 2023-02-27 Univ Pennsylvania Método de purificación escalable para AAV8
CN108603199A (zh) 2015-12-15 2018-09-28 建新公司 用于治疗粘脂贮积症ii型的腺伴随病毒载体
WO2017112948A1 (en) * 2015-12-24 2017-06-29 University Of Florida Research Foundation, Inc. Improved aav production using suspension adapted cells
DK3436593T3 (da) 2016-03-28 2023-02-20 Ultragenyx Pharmaceutical Inc Fremgangsmåder til varmeinaktivering af adenovirus
SG11201808354PA (en) * 2016-03-31 2018-10-30 Spark Therapeutics Inc Column-based fully scalable raav manufacturing process
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
GB201608046D0 (en) 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
KR102392236B1 (ko) 2016-05-18 2022-05-03 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
SG11201809643UA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
GB201612248D0 (en) 2016-07-14 2016-08-31 Puridify Ltd New process
MX2019001938A (es) 2016-08-15 2019-07-04 Genzyme Corp Metodos para detectar aav.
MX2019000935A (es) 2016-08-16 2019-07-04 Regeneron Pharma Metodos para cuantificar anticuerpos individuales de una mezcla.
CA3034527A1 (en) 2016-08-23 2018-03-01 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11795473B2 (en) 2016-10-14 2023-10-24 Ultragenyx Pharmaceutical Inc. Use of tonicifying agents to enhance recombinant adeno-associated virus yield
CN109923411B (zh) 2016-10-25 2022-05-31 里珍纳龙药品有限公司 用于色谱数据分析的方法和***
CA3040288A1 (en) * 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus purification methods
US10626376B2 (en) * 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
JP7142643B2 (ja) 2017-03-22 2022-09-27 ウルトラジェニックス ファーマシューティカル インコーポレイテッド Ｈｄａｃ阻害剤またはｒｅｐタンパク質を伴う細胞培養方法
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CN110913866A (zh) 2017-05-05 2020-03-24 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
MX2020000216A (es) * 2017-06-30 2020-09-03 Spark Therapeutics Inc Metodos de purificacion por columna de vectores aav.
WO2019018342A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. NETWORK EQUIPMENT TRACK GUIDE SYSTEM
JP7221275B2 (ja) 2017-08-03 2023-02-13 ボイジャー セラピューティクス インコーポレイテッド Ａａｖを送達するための組成物および方法
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JP7502991B2 (ja) 2017-10-16 2024-06-19 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症（ａｌｓ）の治療
JP7299896B2 (ja) * 2017-12-29 2023-06-28 武田薬品工業株式会社 アデノ随伴ウイルス精製方法
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
EP3755795A4 (en) 2018-02-19 2022-07-20 Homology Medicines, Inc. ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RECOVERING F8 GENE FUNCTION AND METHODS OF USE THEREOF
WO2019212921A1 (en) * 2018-04-29 2019-11-07 Regenxbio Inc. Scalable clarification process for recombinant aav production
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
CN112770812A (zh) * 2018-07-24 2021-05-07 沃雅戈治疗公司 产生基因治疗制剂的***和方法
JP7070238B2 (ja) * 2018-08-22 2022-05-18 株式会社島津製作所 液体クロマトグラフ分析装置、移動相供給装置、液体クロマトグラフ分析方法および移動相供給方法
CA3112824A1 (en) * 2018-09-21 2020-03-26 Nightstarx Limited Compositions and methods for manufacturing gene therapy vectors
AU2019357039A1 (en) 2018-10-12 2021-06-03 Genzyme Corporation Generation of improved human pah for treatment of severe PKU by liver-directed gene replacement therapy
TW202039854A (zh) 2018-11-16 2020-11-01 美商編碼製藥公司 治療威爾遜氏病的組合物和方法
JP2022530126A (ja) 2019-04-23 2022-06-27 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 新規アデノ随伴ウイルス（ａａｖ）バリアント及び遺伝子治療のためのその使用
US10653731B1 (en) 2019-07-15 2020-05-19 Vigene Biosciences Inc. Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
US10557149B1 (en) 2019-07-15 2020-02-11 Vigene Biosciences, Inc. Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
US10801042B1 (en) 2019-07-15 2020-10-13 Vigene Biosciences, Inc. Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
JP2023513004A (ja) 2020-01-29 2023-03-30 ジェンザイム・コーポレーション 眼科遺伝子療法のための改変されたアデノ随伴ウイルスカプシドタンパク質およびその使用方法
IL295747A (en) 2020-02-21 2022-10-01 Akouos Inc Preparations and methods for the treatment of hearing impairment that is not related to age in humans
EP3919613A1 (en) * 2020-06-05 2021-12-08 Bia Separations D.O.O. Enhanced purification of adeno-associated virus to more effectively remove contaminating dna
WO2021255835A1 (ja) * 2020-06-16 2021-12-23 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 アパタイトカラムを使用したウイルスの精製方法
CN111808828B (zh) * 2020-09-14 2020-11-17 和元生物技术（上海）股份有限公司 腺相关病毒的分离纯化方法
EP4222251A1 (en) 2020-10-01 2023-08-09 Genzyme Corporation Human pah expression cassette for treatment of pku by liver-directed gene replacement therapy
US20240150726A1 (en) 2021-03-09 2024-05-09 Jcr Pharmaceuticals Co., Ltd. Method for Producing Recombinant AAV9 Virion
JP2024511409A (ja) 2021-03-22 2024-03-13 ジェンザイム・コーポレーション 空および完全ａａｖキャプシドのサイズ排除クロマトグラフィー解析
US20230405151A1 (en) 2022-04-12 2023-12-21 Genzyme Corporation Use of irak4 modulators for gene therapy
TW202405430A (zh) 2022-04-12 2024-02-01 美商健臻公司 對於基因療法藥劑的先天免疫原性之樹突細胞試驗
WO2023201274A1 (en) 2022-04-12 2023-10-19 Genzyme Corporation Use of an irak4 modulator for gene therapy
US20230346977A1 (en) 2022-04-13 2023-11-02 Universitat Autònoma De Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
US20230398192A1 (en) 2022-05-16 2023-12-14 Genzyme Corporation Methods of treating metachromatic leukodystrophy
WO2023240062A1 (en) 2022-06-07 2023-12-14 Adverum Biotechnologies, Inc. Melanopsin variants for vision restoration

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143548A (en) 1995-08-30 2000-11-07 Genzyme Corporation Chromatographic purification of adeno-associated virus (AAV)
DK1009808T3 (da) 1997-09-05 2013-01-21 Genzyme Corp Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
WO2006074664A1 (en) * 2005-01-14 2006-07-20 Maxygen Holdings Ltd. Method for purification of factor vii
SG179488A1 (en) * 2007-03-14 2012-04-27 Ligocyte Pharmaceuticals Inc Virus like particle purification
GB2467320A (en) 2009-01-28 2010-08-04 Surrey Nanosystems Ltd Two methods of forming carbon nano-materials using filtered acetylene gas
CA3077531C (en) 2009-06-16 2022-09-20 Genzyme Corporation Improved methods for purification of recombinant aav vectors

Also Published As

Publication number Publication date
US20210139860A1 (en) 2021-05-13
EP3444335A1 (en) 2019-02-20
KR20120047213A (ko) 2012-05-11
EP2443233A4 (en) 2013-05-29
PL2443233T3 (pl) 2017-08-31
RS57784B1 (sr) 2018-12-31
LT3067417T (lt) 2018-11-12
IL253205B (en) 2018-07-31
CA2764176C (en) 2020-06-02
ES2588990T3 (es) 2016-11-08
ES2881050T3 (es) 2021-11-26
EP3067417A2 (en) 2016-09-14
EP3919614A1 (en) 2021-12-08
JP5956331B2 (ja) 2016-07-27
CA3077531A1 (en) 2010-12-23
PT2443233T (pt) 2016-08-17
US20150024467A1 (en) 2015-01-22
LT3444335T (lt) 2021-07-26
CN102803478A (zh) 2012-11-28
HRP20211120T1 (hr) 2021-10-15
SG10201403290SA (en) 2014-10-30
IL216960A0 (en) 2012-02-29
US10017746B2 (en) 2018-07-10
PL3067417T3 (pl) 2019-02-28
US10696952B2 (en) 2020-06-30
ES2693194T3 (es) 2018-12-10
EP2443233A1 (en) 2012-04-25
MX352986B (es) 2017-12-15
JP2019083822A (ja) 2019-06-06
WO2010148143A1 (en) 2010-12-23
IL216960A (en) 2017-07-31
RU2016119739A (ru) 2018-11-05
IL253205A0 (en) 2017-08-31
US11840710B2 (en) 2023-12-12
CY1124323T1 (el) 2022-07-22
IL260215A (en) 2018-07-31
EP2443233B1 (en) 2016-06-01
PT3067417T (pt) 2018-11-13
CY1117936T1 (el) 2017-05-17
US20190010468A1 (en) 2019-01-10
CY1121442T1 (el) 2020-05-29
BRPI1015176A2 (pt) 2017-09-26
CA2764176A1 (en) 2010-12-23
SI3444335T1 (sl) 2021-08-31
RU2012101475A (ru) 2013-07-27
EP3067417B1 (en) 2018-07-25
EP3067417A3 (en) 2016-11-02
CN105861454B (zh) 2020-03-03
MX2011013613A (es) 2012-01-19
SG176283A1 (en) 2012-01-30
DK3444335T3 (da) 2021-07-26
KR101812813B1 (ko) 2017-12-27
HUE054940T2 (hu) 2021-10-28
EP3444335B1 (en) 2021-04-14
KR20180000341A (ko) 2018-01-02
DK3067417T3 (en) 2018-11-19
JP6788056B2 (ja) 2020-11-18
HRP20181743T1 (hr) 2019-02-22
PT3444335T (pt) 2021-07-12
JP2012529917A (ja) 2012-11-29
CN105861454A (zh) 2016-08-17
TR201815937T4 (tr) 2018-11-21
CN102803478B (zh) 2016-04-27
RS62086B1 (sr) 2021-08-31
HUE040636T2 (hu) 2019-03-28
BRPI1015176B1 (pt) 2019-10-29
JP6496684B2 (ja) 2019-04-03
HUE028341T2 (en) 2016-12-28
CA3077531C (en) 2022-09-20
HK1165830A1 (zh) 2012-10-12
JP2016195600A (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
HRP20181743T1 (hr) Poboljšani postupci za pročišćavanje rekombinantnih aav vektora
IL221158B (en) Methods for vector purification of the aav virus
IL225650A0 (en) Protein purification processes
HK1246330A1 (zh) 蛋白質純化
PL2307551T3 (pl) Oczyszczanie wektorów retrowirusowych
IL228610B (en) Buffer system for protein purification
HUE050305T2 (hu) Eljárások izocianát keverékek tisztítására
IL215562A0 (en) Process for isolating therapeutic peptide
SI2552941T1 (sl) Čiščenje vmesnih spojin kaspofungina
EP2519537A4 (en) CLEANING PROTEINS
EP2478010A4 (en) PART PEPTIDE OF LACRITINE
IL231876A0 (en) A system for the purification of viral vectors
GB2479279B (en) Recombinant antigen for detection of toxocariasis